Inovio Pharmaceuticals just slashed its workforce to 112 people and bet the entire company on a single FDA decision for INO-3107. With $58.5 million in cash, a skeptical FDA, and an October deadline, there's almost no room for error.
Imagine your entire company's future depends on a single phone call. Not a portfolio of products. Not a diversified pipeline. One drug. One FDA decision. And you've just sent home nearly everyone who isn't working on it.
That's Inovio Pharmaceuticals right now.
The Skeleton Crew
On March 12, 2026, Inovio announced it had cut its workforce to just 112 employees. That's down from 134 in February 2025, a 16% reduction that eliminated every role not directly tied to one thing: getting INO-3107 across the FDA finish line.
To put 112 people in perspective, that's roughly the size of staff at a single Chipotle location on a busy Friday night. Except instead of rolling burritos, these folks are trying to get a drug approved for a rare disease that has no cure.
The company's logic is brutally simple. Cash is running low ($58.5 million at the end of 2025), the burn rate is roughly $22 million per quarter, and the FDA's decision isn't expected until October 30, 2026. Every dollar spent on anything other than INO-3107 is a dollar wasted. So Inovio took a machete to the org chart.
Total operating expenses already dropped from $112.6 million to $86.9 million in 2025. This latest round of cuts is designed to stretch the company's cash runway into Q4 2026, just barely long enough to survive until the FDA weighs in.
What Exactly Is INO-3107?
INO-3107 targets a disease called recurrent respiratory papillomatosis (RRP), which sounds obscure because it is. HPV strains 6 and 11 cause wart-like growths to sprout inside the throat and airway. These growths can obstruct breathing, wreck your voice, and keep coming back no matter how many times surgeons cut them out.
Think of it like weeding a garden where the roots never die. Some patients need surgery every few weeks. Others go months between procedures, but the papillomas always return.
Until recently, the only option was repeated surgery. There was no approved drug therapy at all. Then in August 2025, a competitor called Papzimeos (zopapogene imadenovec-drba) became the first FDA-approved medical treatment for adult RRP. That approval changed the landscape, and not necessarily in Inovio's favor.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
INO-3107 works differently. It's a DNA-based medicine that trains your immune system's T cells to recognize and attack HPV-infected cells. Patients receive four injections over about nine weeks, delivered intramuscularly with an electroporation device (basically a small electrical pulse that helps the DNA enter cells more efficiently). The idea is to teach the body to fight the virus on its own, rather than relying on a surgeon's blade every few months.
The Data: Promising, but Not Bulletproof
Inovio's case for approval rests on a Phase 1/2 trial of just 32 adult patients. That's a tiny study, even for a rare disease. In the first year after treatment, 72% of patients saw their surgery needs drop by 50% to 100%. About 28% achieved a complete response, meaning they needed zero surgeries for a full twelve months.
The long-term follow-up data is where things get interesting. Researchers tracked 28 of those original patients for a median of 2.8 years total. Without receiving any additional doses, the numbers actually improved: 86% maintained that 50-100% surgery reduction, and half of all responders needed no surgeries whatsoever in the second year.
The safety profile was clean. Most side effects were mild (injection site pain, fatigue), and there were no treatment-related serious adverse events. The results were solid enough to earn publication in Nature Communications and The Laryngoscope.
But (and this is a significant "but"), the FDA has a competitor's data to compare against. Papzimeos posted a 51% complete response rate in its first year, nearly double Inovio's 28.1% year-one CR. Now, cross-trial comparisons are tricky because study designs differ. Still, that gap is hard to ignore, and the FDA is clearly paying attention.
The FDA's Cold Shoulder
This is where the story gets tense.
Inovio submitted its Biologics License Application (BLA) seeking accelerated approval, a faster regulatory pathway the FDA reserves for drugs that treat serious conditions and show meaningful advantage over existing treatments. The agency accepted the application on December 29, 2025, and set that October 30, 2026 review date.
But in the same breath, the FDA dropped a bomb: it told Inovio the company hadn't submitted adequate information to justify accelerated approval eligibility. Translation: "We'll look at your application, but we're not convinced this deserves the fast lane."
Inovio is pushing back. The company plans to request a meeting with the FDA to argue its case for accelerated approval, leaning on the unmet need in RRP and the durability of surgery reduction. Notably, Inovio is not preparing a backup plan under the traditional approval pathway. It's accelerated approval or bust.
That's a gutsy call for a company with 112 employees and a cash countdown clock ticking toward zero.
Wall Street's Verdict Was Swift
When the BLA acceptance news broke in late December (along with the accelerated approval concerns), Inovio's stock cratered 24.45% in a single session, dropping to $1.73 per share. Investors had been hoping for a cleaner regulatory path, and the FDA's skepticism was a bucket of ice water.
Things got more complicated from there. In late January 2026, Inovio extended the expiration of Series A warrants covering 13.5 million shares (with a $1.75 exercise price) from January 28 to March 31, 2026. Warrant extensions like this are a classic sign of a company trying to keep financing options alive while the stock languishes.
And then there are the lawsuits. Multiple securities class actions are pending, with a lead plaintiff deadline of April 7, 2026. The allegations? That Inovio overstated INO-3107's prospects. Whether those suits have merit or are the usual ambulance-chasing that follows biotech stock drops remains to be seen. Either way, they add noise to an already chaotic situation.
The Math That Keeps the CFO Up at Night
Let's run the numbers, because they tell a stark story.
Inovio ended 2025 with $58.5 million in cash and short-term investments, down from $94.1 million at the end of 2024. That's a burn of about $35.6 million in liquid assets over twelve months, even after significant cost-cutting.
With a projected Q1 2026 burn of roughly $22 million, the company should have enough to operate into Q4 2026. The FDA decision is scheduled for October 30. So in theory, the timing works; the money lasts just long enough to get an answer.
In theory.
Anyone who's followed biotech knows that FDA timelines can shift. Review periods sometimes get extended. Complete Response Letters (basically a "try again" from the FDA) can send companies scrambling for more capital at the worst possible moment. And if Inovio needs to raise money with its stock trading near $1.73, the dilution would be painful for existing shareholders.
The 2025 net loss narrowed to $84.9 million, which sounds like progress until you remember the company generates essentially no revenue. Every quarter is a countdown.
A Rare Disease, a Crowded-ish Market
One of Inovio's challenges is that the RRP landscape isn't as empty as it was a year ago. Papzimeos got there first, and first-mover advantage in rare disease can be significant. Physicians and patients already have an approved option.
That said, Inovio's drug has potential advantages. The long-term durability data (improving response rates without additional dosing) is genuinely compelling. If INO-3107 proves that a single course of treatment provides years of benefit, that's a different value proposition than a competing therapy. RRP patients are also a small, tight-knit community. A drug that works well and differently could absolutely find its audience.
INO-3107 also carries Breakthrough Therapy and Orphan Drug designations from the FDA, plus Orphan Drug status in Europe and an Innovation Passport in the UK. These designations bring regulatory perks, including potentially faster reviews and market exclusivity. For a company Inovio's size, that exclusivity matters enormously.
The Biggest Bet in Biotech Right Now
What Inovio is doing isn't unprecedented, but it's unusually stark. Plenty of small biotechs restructure around their lead asset ahead of a big FDA decision. Few do it this visibly, this aggressively, or with this little margin for error.
The company has essentially told the world: "We are INO-3107, and INO-3107 is us." If the drug gets approved, Inovio transforms from a struggling micro-cap into a commercial-stage rare disease company overnight. The Orphan Drug exclusivity alone could be worth the gamble.
If the FDA says no? There's no Plan B drug waiting in the wings. There's minimal cash. There's a workforce that's already been cut to the bone. The company does have a glioblastoma collaboration with Akeso and some early-stage platform work, but those are years away from generating value.
October 30, 2026. That's the date circled on every whiteboard in Inovio's (presumably much emptier) office. Between now and then, 112 people are working to pull off one of the most dramatic all-in bets biotech has seen in years.
No pressure.
Clinical & Regulatory4 min read
The Biotech That Lost 80% of Its Value in a Day (and Is Betting Everything on One More Shot)
Vistagen's stock once surged 1,272% on a single trial result, then cratered 80% when the next one flopped. Now the company has cut 20% of its staff and is betting everything on one final Phase 3 readout that could save or sink the whole operation.
